BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210330
DTEND;VALUE=DATE:20210402
DTSTAMP:20260515T172518
CREATED:20201202T152441Z
LAST-MODIFIED:20201202T152747Z
UID:28146-1617062400-1617321599@www.pharmajournalist.com
SUMMARY:Gene Therapy Comparability
DESCRIPTION:The inaugural Gene Therapy Comparability Summit is the only industry dedicated meeting to ensuring your manufacturing processes are effective and comparable at every stage of development\, supporting a seamless transition to the larger scales required for commercialization. \nThis meeting will unite large pharma and innovative biotechs including Pfizer\, Biogen\, BioMarin and Takeda as they share best practices\, lessons learned and analytical data across the comparability lifecycle. \n \nFocused specifically on enhancing your gene therapy comparability approach\, join us to ensure you maintain safety\, quality\, consistency and efficacy throughout scale-up from clinical to commercial-scale manufacturing\, and satisfy regulatory demands to avoid costly delays to clinical programs. \nIncorporating insights from leading CMC\, Regulatory\, Analytical and Process Development experts\, this is your opportunity to gain extensive technical information on challenges like ensuring manufacturing processes are comparable when changing facilities and cell lines\, developing effective bioassays for use in comparability studies and handling the limited gene therapy lots available. \nJoin your peers online and discover: \n\nHow Biogen defined a robust comparability strategy for late phase gene therapy products\nGain insights into the planning and considerations for a comparability study and risk assessment and understand what defines process comparability vs analytical comparability with Amicus Therapeutics\nHear from the National Institute of Biology and discover if results of non-related analytical methods can be directly compared\nLearn from the Italian Medical Agency and take a deep dive into regulatory expectations for ATMP comparability and comparability exercises\nExplore next generation sequencing (NGS) and how its application can be utilized for comprehensive rAAV genome characterization with Biogen\nBetter understand the challenges associated with limited batch retention and sample availability in the context of comparability and learn best practices for mitigating such challenges with Gyroscope Therapeutics\n\nView the full event guide to find out more!
URL:https://www.pharmajournalist.com/event/gene-therapy-comparability/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210407
DTEND;VALUE=DATE:20210410
DTSTAMP:20260515T172518
CREATED:20210118T081209Z
LAST-MODIFIED:20210118T081209Z
UID:28544-1617753600-1618012799@www.pharmajournalist.com
SUMMARY:Pharma: Clinical 2021
DESCRIPTION:Reuters Events’ Clinical 2021 (April 7-9) is the new home of clinical collaboration\, innovation and discovery. Join hundreds of pharma clinical innovators plus leaders from across the business\, such as real-world evidence\, medical\, and patient centricity\, alongside key regulatory bodies\, providers\, and patient representatives to form new collaborations and gain new insights through presentations\, case-studies\, workshops and collaborative working groups. \nTo know more about Pharma: Clinical 2021 please click here.
URL:https://www.pharmajournalist.com/event/pharma-clinical-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Reuters Events":MAILTO:Saskia.burbach@reutersevents.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210415
DTEND;VALUE=DATE:20210417
DTSTAMP:20260515T172518
CREATED:20210226T104524Z
LAST-MODIFIED:20210226T111548Z
UID:29170-1618444800-1618617599@www.pharmajournalist.com
SUMMARY:MarketsandMarkets qPCR and dPCR Virtual Conference
DESCRIPTION:Advancing qPCR and dPCR technological developments and its applications in oncology and infectious disease diagnostics \nAs per MarketsandMarkets research analysis\, the global dPCR and qPCR is estimated to grow to USD 6\,270.9 million by 2024 at a CAGR of 8.8%. Factors such as the rising incidences of target infectious diseases and genetic disorders; continuous technological advancements in PCR technologies; increasing investments\, funds\, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However\, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use \n \nMarketsandMarkets are proud to host its inaugural “qPCR and dPCR Virtual Conference” which will be held on 15th – 16th April 2021. The conference will focus on the latest developments in digital and real time PCR and also\, its application in cancer diagnosis and infectious disease diagnostics \nEvent Website: https://events.marketsandmarkets.com/marketsandmarkets-qpcr-and-dpcr-virtual-conference/  \nRegistration link:  https://events.marketsandmarkets.com/marketsandmarkets-qpcr-and-dpcr-virtual-conference/
URL:https://www.pharmajournalist.com/event/marketsandmarkets-qpcr-and-dpcr-virtual-conference/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210420
DTEND;VALUE=DATE:20210422
DTSTAMP:20260515T172518
CREATED:20201126T154428Z
LAST-MODIFIED:20201207T142117Z
UID:28066-1618876800-1619049599@www.pharmajournalist.com
SUMMARY:AI Driven Drug Repositioning and Repurposing Summit
DESCRIPTION:The AI Driven Drug Repositioning & Repurposing Summit will bring together 80+ leaders in repurposing and pioneers in AI and machine learning to strategize how repurposing can reach its full potential to: \n\nImprove time and cost savings of drug development\nLeverage the safety advantage in reducing development risk\nUnlock market potential advantage\nImprove return on investment for repurposed drugs\nExplore out-licensing options\n\nThis meeting aims to help pharma\, biotech and academics stay ahead of the curve in their repurposing endeavors during a period exploding with new technologies. Join cutting-edge discussions with the like of AstraZeneca\, BenevolentAI\, and Healx\, to solve ongoing technical challenges surrounding AI tools in repurposing\, understand the delicate risk-reward balance in potential repurposing opportunities and explore lessons learned from AI applications in repurposing during Covid-19. \nFeaturing 2 days of jam-packed content\, this digital summit will provide you with all the information you need to begin implementing AI tools into repurposing projects within your organization. What’s more\, our digital platform allows you to take part in live Q&A with the presenters\, take a tour of the virtual exhibition\, and even join online rooms where you can join targeted interactive discussion groups! \nTo know more about AI Driven Drug Repositioning and Repurposing Summit please click here.
URL:https://www.pharmajournalist.com/event/ai-driven-drug-repositioning-and-repurposing-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210420
DTEND;VALUE=DATE:20210423
DTSTAMP:20260515T172518
CREATED:20201224T123305Z
LAST-MODIFIED:20201224T123305Z
UID:28380-1618876800-1619135999@www.pharmajournalist.com
SUMMARY:Anti-Infectives Drug Development – Digital Summit
DESCRIPTION:Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater\, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments\, biopharma\, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance. \nWith some now considering the field as the new ‘Wall Street darling’\, especially given the $1 billion launch of the AMR action fund\, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs. \n \nBringing together 60+ senior leaders from large pharma\, innovative biotech\, academia and investment companies\, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates\, novel modalities and effective strategies\, that address market sustainability and aim for superiority. \nWhat you can expect: \n\nReimagine anti-infective drug development to ensure economic sustainability\, with insight from Merck\, CARB-X & AlloVir\n\n\nExplore the non-traditional approaches employed to combat multi-drug resistance\, with insight from Locus Biosciences\, Peptilogics & SciBac\n\n\nAdvance the clinical superiority of anti-infectives to drive commercial success\, with insight from ContraFect & Summit Therapeutics\n\n\nTarget the unmet medical need to ensure drug development pipeline success\, with insight from BioVersys\, Entasis Therapeutics & Spero Therapeutics\n\n\nDiscover superior novel strategies to combat anti-microbial resistance\, with insight from Techulon\, MicuRX & Princeton University\n\nTo know more about Anti-Infectives Drug Development please click here.
URL:https://www.pharmajournalist.com/event/anti-infectives-drug-development-digital-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210422
DTEND;VALUE=DATE:20210424
DTSTAMP:20260515T172518
CREATED:20210301T101134Z
LAST-MODIFIED:20210301T101134Z
UID:29204-1619049600-1619222399@www.pharmajournalist.com
SUMMARY:4th Annual MarketsandMarkets Real-World Data\, Life Sciences Analytics and Market Access Virtual Conference (Time Zone - EST)
DESCRIPTION:MarketsandMarkets is proud to announce the 4th Annual MarketsandMarkets Real-World Data\, Life Sciences Analytics and Market Access Virtual Conference to be held on 22- 23 April\, 2021. \nWhile the 3rd annual virtual conference had discussions on how the insights derived from real world data\, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators\, doctors\, and payers\, the 4th Annual conference will focus on discussion about the application of RWD/RWE across the life cycle. The event will discuss Impact of COVID-19 on the real-world generation and making sense of the Electronic Health Records data for COVID-19. \nOur aim for the 4th Annual Virtual Conference is to unite all stakeholders in a virtual room to learn how to overcome the challenges caused due to the pandemic\, efficiently and effectively generating RWE for stakeholders including payers\, patients and physicians. \nEvent Website https://events.marketsandmarkets.com/4th-edition-marketsandmarkets-real-world-data-life-sciences-analytics-and-market-access-virtual-conference-uk-eu/ \nRegistration link:  https://events.marketsandmarkets.com/4th-edition-marketsandmarkets-real-world-data-life-sciences-analytics-and-market-access-virtual-conference-uk-eu/register 
URL:https://www.pharmajournalist.com/event/4th-annual-marketsandmarkets-real-world-data-life-sciences-analytics-and-market-access-virtual-conference-time-zone-est/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210426
DTEND;VALUE=DATE:20210428
DTSTAMP:20260515T172518
CREATED:20201124T092500Z
LAST-MODIFIED:20201124T092658Z
UID:28055-1619395200-1619567999@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes East Coast 2021
DESCRIPTION:SMi are proud to announce the 8th Pre-filled Syringes East Coast virtual conference taking place on 26th and 27th April 2021. \nThe global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry\, is expected to exceed $9.7 billion by 2025. With that in mind\, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation\, new digital technology trends\, human studies and innovative design and delivery systems within the prefilled syringe industry. \nThis comprehensive overview will help attendees understand the changing global market and the challenges faced within the industry. The upcoming conference will cover key topics driving the industry including advancing development for drug delivery devices\, regulatory updates including the FDA draft guidance on bridging studies\, connectivity and digital health for combination products and compatibility for drug delivery systems. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nWe look forward to welcoming you to the conference in April 2021. \n \nWho should attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers\n\nTo register or for more information visit: www.pfsamericas.com/pjwl \nBenefit of attending:  \nPre-Filled Syringes East Coast will explore the latest industry updates on pre-filled syringes exploring considerations for platforms and integrated development. Gain insights into how the industry has overcome challenges of the pandemic with case studies on human factors studies and the acceleration towards connectivity for delivery devices. Hear from leading industry and regulatory experts on life cycle management\, guidance on bridging studies and biocompatibility considerations. \nThe SMi Virtual Conference Platform will deliver the following benefits: \n\nLive and On Demand speaker content: Get access to the latest strategies and case studies from your marketplace online!\nNetwork with all the event attendees: Connect\, see who’s attending\, chat and share contact details with all online delegates\, speakers and sponsors\nExhibit a Virtual Booth: You can pack your customized booth full of documents\, videos and even show who is manning the booth during the event and hosting meetings\nHost & Join Meetings & Socials: Join preferred speaking sessions\, host you own meetings and even a virtual Networking social\, with in built Zoom functionality\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk\nTwitter: @SMiPharm #Smipfsusa\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-east-coast-2021/
LOCATION:Virtual conference: Online access only
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210426
DTEND;VALUE=DATE:20210429
DTSTAMP:20260515T172518
CREATED:20210208T084959Z
LAST-MODIFIED:20210208T084959Z
UID:28858-1619395200-1619654399@www.pharmajournalist.com
SUMMARY:Strategic Operational Excellence in Life Sciences
DESCRIPTION:Strategic Operational Excellence in Life Sciences is a brand new forum\, designed for and by strategic operations and operational excellence leaders in the Life Sciences\, with a vision to create a holistic\, enterprise-wide dialogue around business excellence innovation\, to ultimately redefine operational excellence as a competitive advantage for the modern scientific organization. \nIt will shine a light on the boldest operational excellence leaders from the most admired biopharma and medical devices businesses\, sharing their stories of process excellence innovation\, nurturing cultures of continuous improvement and re-examining supply chain operations during and beyond Covid-19. \nTo know more about Strategic Operational Excellence in Life Sciences please click here.
URL:https://www.pharmajournalist.com/event/strategic-operational-excellence-in-life-sciences/
LOCATION:Exclusive Virtual Conference
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210427
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172518
CREATED:20210115T080512Z
LAST-MODIFIED:20210115T080512Z
UID:28488-1619481600-1619740799@www.pharmajournalist.com
SUMMARY:Interstitial Lung Disease Drug Development Summit
DESCRIPTION:Network with over 50 other industry pioneers including Ionis Pharmaceuticals\, Genentech\, Vicore and AnaMar to hear first-hand how the latest scientific research is innovating and upgrading ILD therapeutics at this trailblazing new meeting. \n \nThe 1st Interstitial Lung Disease Drug Development Summit is a ground-breaking new conference dedicated to helping you drive forward the development of effective therapies for chronic fibrosing ILDs and achieve success in anti-fibrotic drug development beyond IPF. \nVisit our website to download our event guide.
URL:https://www.pharmajournalist.com/event/interstitial-lung-disease-drug-development-summit/
LOCATION:Virtual Conference
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210427
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172518
CREATED:20210118T174336Z
LAST-MODIFIED:20210118T174336Z
UID:28564-1619481600-1619740799@www.pharmajournalist.com
SUMMARY:3rd Neuroimmunology Drug Development Summit
DESCRIPTION:As diverse programs are advancing towards the clinic\, there is a dire need to tackle the many translational challenges neuro-immunologists are facing to develop clinically effective neuroimmunology targeted therapeutics. \n \nBuilding on the success of last year’s meeting\, the 3rd Neuroimmunology Drug Development Summit will uncover how leading companies in this emerging field are discovering immune-modulating targets and deploying immuno-neurology across clinical case studies. As we gather the best minds in this infant field we will put a spotlight on the latest key learnings across microglia\, astrocytes\, STING\, TREM2 and more to help pave the way to translating key technological and mechanistic insights towards the clinic. \nJoin this intimate\, industry led forum to not only learn from those pioneering the field\, but to network and build meaningful partnerships with 80+ neuroimmunology drug development experts. \nTo find out more and view the 2021 speaker line-up\, download the 2021 event guide.
URL:https://www.pharmajournalist.com/event/3rd-neuroimmunology-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210427
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172518
CREATED:20210121T100547Z
LAST-MODIFIED:20210121T100547Z
UID:28587-1619481600-1619740799@www.pharmajournalist.com
SUMMARY:Mitochondria-Targeted Drug Development Digital Summit
DESCRIPTION:The Mitochondria-Targeted Drug Development Digital Summit is the only industry-led meeting focused on end-to-end mitochondria-targeting. Explore success stories from leading experts overcoming common challenges whilst exploring what’s next to help you accelerate your pipeline into the clinic. \nWith 20+ hours of content\, 2 interactive workshops and over 5 hours of networking with key industry leaders from Larimar Therapeutics\, Minovia Therapeutics\, Mitokinin and many more\, this comprehensive forum will completely focus on mitochondria-targeting drug development and the current challenges and opportunities in the field. \n \nMake this your 2021 must-attend meeting and network with 80+ senior CSOs\, CEOs\, research scientists\, academics and investors committed to targeting mitochondria to tackle challenges with Mitochondrial & Age-related Diseases. \nIn this focused summit\, you’ll learn from the field’s pioneers who’ll be sharing their experience in: \n\nExploring the role of mitochondrial dysfunction in age-related diseases & rare genetic mitochondrial diseases\nExamining early discovery and research findings\nEvaluating preclinical drug development and studies\nDiscovering the patient perspective to aid mitochondria-targeted drug development\nAssessing clinical development and showcasing current trials\nLessons learned from clinical trial design and how design can be improved to mitigate common challenges\nRealizing the use of gene therapy\, editing technology and innovation\n\nTo know more about Mitochondria-Targeted Drug Development Digital Summit please click here.
URL:https://www.pharmajournalist.com/event/mitochondria-targeted-drug-development-digital-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210428
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172518
CREATED:20210122T095626Z
LAST-MODIFIED:20210122T095626Z
UID:28611-1619568000-1619740799@www.pharmajournalist.com
SUMMARY:SMi’s 4th Annual Pharmaceutical Microbiology East Coast Conference
DESCRIPTION:Sponsor: Microcoat \nChaired by Lynne Ensor\, Vice President\, RCS Head of Global Compliance\, Parexel \nExploring Agile Contamination Control Strategy \nBiologic products require diligent microbial control because of their complex and sometimes growth-promoting manufacturing processes\, and high-risk patient populations. The increase in complexity of pharmaceutical products\, rise in development of biologics and increasingly stringent regulations for biologics are some of the factors that are driving the growth of the pharmaceutical microbiology market for biopharmaceutical products. \n \nSMi Group invite all microbiologists to join the virtual conference to discuss Contamination Control Strategies\, Effective Environmental Monitoring\, and the newest schools of thought in personnel operation. Leaders in regulation and compliance will provide expert viewpoints on how to implement and interpret the regulation\, in addition\,  Annex 1 will be assessed and debated. \nThe industrial microbiology market is made up of equipment and systems. The equipment comprises the filtration pumps & systems\, microbial detection systems\, air monitoring systems\, incubators & culture apparatus\, etc. This equipment is used in series of microbiological tests by the industry\, where they play a vital role as they provide the ease in the testing procedure. In industrial microbiology test types\, microbial tests are carried out to study the total viable count of the specific organism present in a solution. \nThe Microbiological industry continues to swell and is set to reach a Record CAGR of 7.1% Rise in Growth by 2024. The Global Clinical Microbiology Market is expected to reach USD 4.95 billion by 2023. \nEvent Hashtag: #SMiPharmaMicroEC \nHighlights for 2021: \n\nEXPLORE the latest advancements in robust risk-based disinfection strategies for effective cleaning and microbe elimination\nINVESTIGATE the extensive and complex regulatory landscape alongside the regulators\nDELVE into recent case studies delivered by experts in microbial monitoring and contamination control programs\nATTAIN expert tuition at the post-conference workshops in new quality risk management tools for contamination control and the latest revisions in the USP\nVIRTUAL CONFERENCE benefits include: virtual exhibition booths packed with information\, networking features to discuss and share contact details with other attendees\, and virtual meetings and networking socials\n\n2 Interactive Pre-Conference Workshops on April 27\, 2021 \nWorkshop A: USP Microbiology 2021 – Keeping Up with Standards \nLed by: Donald Singer\, Microbiology Expert Committee Chair\, US Pharmacopoeia \nWorkshop B: Quality Risk Management Tools for Contamination Control \nLed by: Cheryl Essex\, Head of Microbiological Control for Biologics\, Sanofi and Jon Williams\, Global Proactive Risk Manager\, Sanofi \nView the full agenda: www.microbiologyeastcoast.com  \nWHO SHOULD ATTEND? \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist\, Drug Substance External Manufacturer\, QC Scientists\, Heads of Quality\, Business Development Manager\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist
URL:https://www.pharmajournalist.com/event/smis-4th-annual-pharmaceutical-microbiology-east-coast-conference/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210428
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172518
CREATED:20210208T082114Z
LAST-MODIFIED:20210208T082114Z
UID:28846-1619568000-1619740799@www.pharmajournalist.com
SUMMARY:Triple Negative Breast Cancer Drug Development Digital Summit
DESCRIPTION:Improving the Safety\, Efficacy & Predictability of Monotherapy & Combinatorial Therapies to Fast-track the Discovery & Development of TNBC Treatments to Reach Patients in Need \nThis is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer. \nBreast cancer (BC) is the most common solid tumor in women\, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence. \nGiven the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress\, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summit has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint\, DDR inhibitor\, ADC and other novel agents. \nThis is the industry’s definitive conference specifically dedicated to advancing the development of both monotherapy and combinatorial therapies to improve the current standard of care for patients with TNBC. \nJoin leading experts from CytoDyn\, Zenith Epigenetics\, Oncorus\, University of Pittsburgh and more who are identifying specific molecular targets\, such as immune checkpoint modulators\, intra-nuclear targets\, intracellular targets\, and cell surface targets\, to limit the progression and metastasis of this invasive tumor and improve patient outcomes. \nWhether you are developing a TROP2-ADC\, a PARP inhibitor\, a viral immunotherapy or a cancer vaccine for treating TNBC\, this dedicated digital meeting is your opportunity to discuss novel\, cutting edge targeted therapies in TNBC and get a full picture of the clinical landscape. \nTo know more about Triple Negative Breast Cancer Drug Development Digital Summit please click here.
URL:https://www.pharmajournalist.com/event/triple-negative-breast-cancer-drug-development-digital-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210428
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172518
CREATED:20210222T084218Z
LAST-MODIFIED:20210222T084218Z
UID:29072-1619568000-1619740799@www.pharmajournalist.com
SUMMARY:The 4th Global NASH Congress
DESCRIPTION:The Global NASH Congress programme creates a collaborative environment in which you can create enduring relationships across the full range of disciplines engaged in NASH research & drug discovery and development. \n \n\nLearn how to integrate NAFLD Screening into secondary and tertiary care\nDiscover the regulatory pathways for approval of biomarkers in NAFLD patients\nReview the current and potential biomarkers for staging\nInvestigate if targeting fructose metabolism offers a NAFLD/NASH therapy\nHear how belapectin\, a galectin-3 (Gal-3) inhibitor\, is in development for the prevention of oesophagal varices in patients with NASH cirrhosis\nExplore the Epidemiology of NAFLD\n\nTo know more about The 4th Global NASH Congress please click here.
URL:https://www.pharmajournalist.com/event/the-4th-global-nash-congress/
LOCATION:Online & on-demand
ORGANIZER;CN="Global Engage":MAILTO:nnoakes@globalengage.co.uk
END:VEVENT
END:VCALENDAR